History & milestones

Our Story 

Vitrolife was established in Sweden in 1994 when the field of assisted reproduction was still young.

The possibility to help people become parents through assisted reproduction became a reality in the 1960s, following the development of a method for fertilising eggs outside the body. The birth of Louise Brown in 1978 – the first baby born as a result of in vitro fertilisation (IVF) – gave new hope to men and women suffering from infertility.

As IVF techniques developed the importance of individual components on IVF success began to be understood. The founders of Vitrolife realised the value of using culture media with consistent and repeatable performance; the manufacturing and delivering of the LOT-to-LOT consistency they developed is still significant for Vitrolife today.

Through well-executed product development, consistent quality controls and the acquisition of other innovative IVF companies, Vitrolife has grown with the market globally. As a result, Vitrolife provides an unbroken chain of quality products, securing results at every step of IVF treatment. Only Vitrolife can guarantee every link in this chain.

Our commitment to increase pregnancy rates has never been more dedicated. Together with equally devoted clinics, we are improving IVF success and fulfilling more couples’ greatest dream. We are very proud to be a part of making this happen.

Milestones

2017

 

 

   
  • Launch of RapidVit™ Omni and RapidWarm™ Omni for vitrification and warming of oocytes through to blastocyst stage embryos.

2016

 

  • Launch of EmbryoScope+ time-lapse incubator, for undisturbed culture and improved selection of embryos.
  • Acquisition of OCTAX Microscience GmbH and MTG Medical Technology Vertriebs-GmbH, jointly holding a world-leading position in laser technology for IVF.

2015

 

  • Launch of RapidVit™ Oocyte and RapidWarm™ Oocyte for oocyte vitrification.
  • Launch of the Time-lapse by Vitrolife concept. Complete time-lapse systems - from optimised culture medium to fully integrated bench-top incubators.

2014

 

  • Launch of G-TL™ – the first culture medium specially designed for time-lapse.
  • Acquisition of Unisense FertiliTech A/S, the market leader within the field of time-lapse for IVF, with the product EmbryoScope® time-lapse system.
  • Vitrolife became ISO 14001 certified.

2013

 

  • Vitrolife acquired all the shares in HertART Aps.
  • Launch of Vitrolife Labware – exclusively certified for human IVF.

2012

 

  • Acquisition of Cryo Management Ltd, one of the world’s leading players within time-lapse for IVF, developer of Primo Vision™ time-lapse embryo monitoring system.
  • Launch of SpermGrad™ kits, ready-to-use.
  • Thomas Axelsson is appointed CEO.

2011

 

  • First company in China to receive regulatory approval for an entire IVF culture media portfolio.
  • Launch of SpermFreeze Solution™ for cryopreservation of sperm.
  • Patent for the Sense™ needle in Europe was obtained, which meant both design protection and product patent protection.

2010

 

  • Collaboration agreement was entered with the Danish company HertART Aps with regard to product development and distribution of IVF labware and at the same time a participation of 25 percent in the company was acquired.
  • Launch of Rapid-i Vitrification System.
  • Acquisition of the business in Conception Technologies, USA, which broadened the IVF product portfolio with an extensive line of micropipettes.  

2009

 

  • New market organisation established in Beijing, China.
  • New market organisation established in Tokyo, Japan.
  • Acquisition of the distributor IVF Ltd. operating in Great Britain and Ireland.

2008

 

  • Launch of Sense™, a unique oocyte aspiration needle.
  • Acquisition of majority shareholding in the Italian distributor A.T.S. Srl. 

2007

 

  • Launch of a new product series for embryo culture - the G5 Series™.
  • Launch of vitrification media RapidVit™ Blast and RapidWarm™ Blast.
  • Received sales approval for fertility media from the Australian Medical Products Agency, TGA, as one of the first companies outside Australia.

2006

 

  • Swemed Lab was acquired and the product portfolio was extended with micropipettes and oocyte retrieval needles for in vitro fertilisation.

2005

 

  • Launch of the new product line GIII-Series™ PLUS, media from the GIII Series™ supplemented with human albumin (ready-to-use).

2004

 

  • Vitrolife received marketing approval from FDA for new products within Assisted Reproductive Technology (ART) and CE mark for G-FreezeKit Blast™, G-ThawKit Blast™, G-PGD™ and G-OOCYTE™. The first CE marked products for human IVF in the world.
  • A patent regarding the use of recombinant albumin with or without hyaluronic acid in media for embryos and stem cells is approved in USA.

2003

 

  • Launch of EmbryoGlue®, an implantation promoting medium.
  • A patent was granted in USA for a new, rapid-freeze storage technique for living cells, called Vitroloop®.
  • Magnus Nilsson is appointed CEO.

2002

 

  • Launch of GIII-series™, a new culture media series.
  • The first commercial media products were shipped from the Kungsbacka production facility in Sweden and the first products were distributed to American customers from the facility in Denver, US.

2001

 

  • Beyond HSA – Recombinant media r-S1™/ r-S2™ was developed and launched.
  • The Vitrolife share was listed on the Stockholm Stock Exchange’s O-list in conjunction with a new share issue of SEK 160 million.

2000

 

  • A merger of equals was completed with Fermentech. Skanditek hereby becomes the largest shareholder in the merged company, which trades under the name Vitrolife.

1998

 

  • First sequential media G-1™ and G-2™ was developed and launched.


1996

 

 


 

  • A fully developed and complete product portfolio of IVF-media was presented.

1994

 

  • Vitrolife was founded.
  • The first IVF-product, an ICSI medium, was initiated in collaboration with Dr. Gardner in Denver, Colorado, US. Later on it was also launched as the first commercial ICSI medium.